Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The source filing: Cytokinetics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:30 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338217
FAQ
- What is Cytokinetics's D&A?
- Cytokinetics (CYTK) reported D&A of $3.63M in Q2 2026.
- How has Cytokinetics's D&A changed year-over-year?
- Cytokinetics's D&A increased by 58.9% year-over-year, from $2.29M to $3.63M.
- What is the long-term trend for Cytokinetics's D&A?
- Over 4 years (2021 to 2025), Cytokinetics's D&A has grown at a 45.2% compound annual growth rate (CAGR), from $2.28M to $10.13M.
- What does D&A mean?
- Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.
Ask your AI about Cytokinetics's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude